GlassScriptPhysician profile
Erin K Willits
NPI 1962766402
$5,738.84
in general payments reported to CMS, 2019-2025
28 companies · $632 in 2025
The $632 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $138 · 2020: $755 · 2021: $905 · 2022: $775 · 2023: $1,626 · 2024: $908 · 2025: $632.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,166.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,166.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,187.51 | 2020-2025 | Fasenra, Breztri, Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $964.61 | 2020-2025 | Hyqvia, Cuvitru, Takhzyro |
| Genzyme Corporation | $599.80 | 2020-2025 | |
| Regeneron Healthcare Solutions, INC. | $436.60 | 2020-2025 | Dupixent |
| Glaxosmithkline, LLC. | $433.46 | 2020-2024 | Nucala, Trelegy Ellipta, Arexvy |
| Csl Behring | $360.19 | 2020-2025 | Hizentra, Haegarda |
| Pharming Healthcare, INC. | $307.55 | 2019-2025 | Ruconest |
| Pfizer INC. | $208.04 | 2020-2025 | |
| Genentech USA, INC. | $153.88 | 2021-2025 | Xolair |
| Novartis Pharmaceuticals Corporation | $139.71 | 2021-2025 | |
| Amgen INC. | $130.76 | 2022-2025 | Tezspire |
| Teva Pharmaceuticals USA, INC. | $116.21 | 2021 | |
| Grifols USA, LLC | $114.00 | 2020-2021 | |
| Biocryst US Sales Co., LLC | $106.67 | 2021-2025 | Orladeyo |
| Abbvie INC. | $74.37 | 2022-2023 | Rinvoq |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $71.98 | 2020-2024 | Auvi-Q |
| Incyte Corporation | $57.84 | 2021-2023 | Opzelura |
| Cycle Pharmaceuticals INC | $50.07 | 2025 | Sajazir |
| Ars Pharmaceuticals Operations, INC. | $38.10 | 2025 | Neffy |
| Biohaven Pharmaceutical Holding Company LTD. | $29.09 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.95 | 2020 | |
| Octapharma USA, INC. | $23.33 | 2020 | |
| Adma Biomanufacturing LLC | $22.70 | 2021 | |
| Bio Products Laboratory USA, INC. | $19.43 | 2021 | |
| Merck Sharp & Dohme LLC | $19.33 | 2023 | |
| Blueprint Medicines Corporation | $17.90 | 2023 | Ayvakit |
| Aimmune Therapeutics, INC. | $16.29 | 2021 | |
| Biocryst Pharmaceuticals, INC. | $14.47 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Willits listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.